ArticlePloS one2025
Tumour-associated macrophages in human meningiomas.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of tumor-associated macrophages in the progression and recurrence of meningiomas.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumour-associated macrophages (TAMs) are regarded as potential therapeutic targets due to "pro-tumoral" and "anti-tumoral" phenotypes. Human meningiomas contain considerable number of TAMs, but their clinical impact is sparsely investigated in these tumours. The aim of this study was therefore to investigate the presence, morphology, and distribution of TAMs in human meningiomas, and relate these findings to histopathology, meningioma subtypes, World Health Organization (WHO) grade, risk of recurrence, and overall survival. In this study, 147 WHO grade 1 and 2 primary meningiomas prepared as tissue micro arrays were included. Standard immunohistochemistry, with the antibodies Iba1 as a pan-marker for "all TAMs", iNOS for M1 and Arginase 1 for M2 TAMs, was performed to investigate their infiltration in the meningioma tissue. The immunostainings were scanned and analysed digitally. TAMs were found in most of the meningiomas with varying amount of ramified and amoeboid appearances. The quantity of total TAMs (Iba1-stained) was found to be significantly higher in the age group ≥ 60 years compared with the younger age group. M2 cell dominated over M1 cell quantity, and a higher quantity of M2 TAMs was found in skull-base compared with non-skull base tumours. Meningothelial subtypes had a higher quantity of M2 TAMs compared with transitional and atypical ones. Furthermore, the M1/M2-ratio was higher in meningiomas linked to the convexities compared with tumours in the basal. No relations between TAMs and histological WHO grade or prognosis (time to recurrence and overall survival) were found. TAMs were common in our series of meningiomas. However, their infiltration showed no clinicopathological significance. Due to their complex dynamic characteristics and shifting phenotypes, the investigation of these immune cells is demanding. Therefore, the TAMs' definite role in human meningiomas in relation to clinicopathological parameters and prognosis need to be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.